Compare LNC & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LNC | DVA |
|---|---|---|
| Founded | 1905 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Misc Health and Biotechnology Services |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 8.2B |
| IPO Year | N/A | 2002 |
| Metric | LNC | DVA |
|---|---|---|
| Price | $39.90 | $150.73 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 12 | 4 |
| Target Price | $45.92 | ★ $156.75 |
| AVG Volume (30 Days) | ★ 1.8M | 1.4M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | ★ 4.49% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 9.84 |
| Revenue | N/A | ★ $13,643,069,000.00 |
| Revenue This Year | $11.29 | $3.80 |
| Revenue Next Year | $3.74 | $3.04 |
| P/E Ratio | ★ $7.17 | $15.32 |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $27.58 | $101.00 |
| 52 Week High | $46.82 | $157.12 |
| Indicator | LNC | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 42.91 | 70.37 |
| Support Level | $39.65 | $146.08 |
| Resistance Level | $42.25 | $152.67 |
| Average True Range (ATR) | 1.39 | 6.41 |
| MACD | 0.11 | 1.36 |
| Stochastic Oscillator | 27.21 | 91.83 |
Lincoln National Corp operates multiple insurance and retirement businesses. The company's operating segment includes Annuities; Retirement Plan Services; Life Insurance and Group Protection. Its products include fixed and indexed annuities, variable annuities, universal life insurance (UL), variable universal life insurance (VUL), linked-benefit UL and VUL, indexed universal life insurance (IUL), term life insurance, employer-sponsored retirement plans and services, and group life, disability and dental.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.